Morocco’s medicines agency has launched an urgent recall of a batch of the neonatal drug Curosurf after detecting a potential microbial contamination risk that could affect patient safety in healthcare facilities.
The Moroccan Agency for Medicines and Health Products said the measure, taken in coordination with Promopharm, concerns batch number 1212121 of Curosurf 120 mg in 1.5 ml vials. The drug, whose active substance is poractant alfa, is used mainly in hospitals to treat respiratory distress in premature newborns whose lungs are not fully developed.
The agency called on hospital and retail pharmacists, wholesale distributors and healthcare institutions to stop dispensing, distributing or using the affected batch immediately, quarantine available stock and arrange its return as quickly as possible through Promopharm under the approved recall procedure.
The recall forms part of Morocco’s drug vigilance system, which is designed to monitor medicine quality and allow rapid intervention when potential risks to patients emerge.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.